Literature DB >> 23026029

Delving deeper: MCL-1's contributions to normal and cancer biology.

Rhonda M Perciavalle1, Joseph T Opferman.   

Abstract

BCL-2 molecules are regulators of programmed cell death and defects in this pathway contribute to human diseases. One family member, MCL-1, is unique because its expression is tightly regulated and it is essential for promoting the survival of myriad cellular lineages. Additionally, MCL-1 promotes the maintenance of normal mitochondrial morphology and energy production. Dissection of these functions revealed recently that they depend on separate mitochondrial sublocalizations. MCL-1's antiapoptotic activity is restricted to the outer mitochondrial membrane (OMM), whereas its function in mitochondrial physiology requires localization to the matrix. These findings provide an attractive model for how MCL-1's diverse functions may contribute to normal cell homeostasis and function. MCL-1 is highly amplified in human cancer, suggesting that these functions may contribute to malignant cell growth and evasion of apoptosis.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23026029      PMCID: PMC3532576          DOI: 10.1016/j.tcb.2012.08.011

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  91 in total

1.  Regulation of mitochondrial structure and function by the F1Fo-ATPase inhibitor protein, IF1.

Authors:  Michelangelo Campanella; Edward Casswell; Stephanie Chong; Ziad Farah; Mariusz R Wieckowski; Andrey Y Abramov; Andrew Tinker; Michael R Duchen
Journal:  Cell Metab       Date:  2008-07       Impact factor: 27.287

2.  Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1.

Authors:  Catherine L Day; Callum Smits; F Cindy Fan; Erinna F Lee; W Douglas Fairlie; Mark G Hinds
Journal:  J Mol Biol       Date:  2008-06-04       Impact factor: 5.469

3.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Authors:  Christin Tse; Alexander R Shoemaker; Jessica Adickes; Mark G Anderson; Jun Chen; Sha Jin; Eric F Johnson; Kennan C Marsh; Michael J Mitten; Paul Nimmer; Lisa Roberts; Stephen K Tahir; Yu Xiao; Xiufen Yang; Haichao Zhang; Stephen Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 4.  Brick by brick: metabolism and tumor cell growth.

Authors:  Ralph J Deberardinis; Nabil Sayed; Dara Ditsworth; Craig B Thompson
Journal:  Curr Opin Genet Dev       Date:  2008-04-02       Impact factor: 5.578

5.  The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages.

Authors:  Ivan Dzhagalov; Alexis Dunkle; You-Wen He
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

Review 6.  Unique biology of Mcl-1: therapeutic opportunities in cancer.

Authors:  Matthew R Warr; Gordon C Shore
Journal:  Curr Mol Med       Date:  2008-03       Impact factor: 2.222

7.  Characterization of PINK1 processing, stability, and subcellular localization.

Authors:  William Lin; Un Jung Kang
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

8.  Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage.

Authors:  Nicole Arbour; Jacqueline L Vanderluit; J Nicole Le Grand; Arezu Jahani-Asl; Vladimir A Ruzhynsky; Eric C C Cheung; Melissa A Kelly; Alexander E MacKenzie; David S Park; Joseph T Opferman; Ruth S Slack
Journal:  J Neurosci       Date:  2008-06-11       Impact factor: 6.167

9.  A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.

Authors:  Jiannong Li; Jean Viallet; Eric B Haura
Journal:  Cancer Chemother Pharmacol       Date:  2007-05-16       Impact factor: 3.333

10.  A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation.

Authors:  Erinna F Lee; Peter E Czabotar; Mark F van Delft; Ewa M Michalak; Michelle J Boyle; Simon N Willis; Hamsa Puthalakath; Philippe Bouillet; Peter M Colman; David C S Huang; W Douglas Fairlie
Journal:  J Cell Biol       Date:  2008-01-21       Impact factor: 10.539

View more
  105 in total

1.  FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation.

Authors:  C Feng; F Yang; J Wang
Journal:  Cancer Gene Ther       Date:  2017-08-04       Impact factor: 5.987

Review 2.  Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members.

Authors:  Joseph T Opferman
Journal:  FEBS J       Date:  2015-09-15       Impact factor: 5.542

Review 3.  Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins.

Authors:  Nana Zheng; Zhiwei Wang; Wenyi Wei
Journal:  Int J Biochem Cell Biol       Date:  2016-02-06       Impact factor: 5.085

Review 4.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

Authors:  Peter E Czabotar; Guillaume Lessene; Andreas Strasser; Jerry M Adams
Journal:  Nat Rev Mol Cell Biol       Date:  2014-01       Impact factor: 94.444

5.  Guarding effector T-cell survival: all for one, Mcl-1 for all?

Authors:  E Ottina; M Pellegrini; A Villunger
Journal:  Cell Death Differ       Date:  2013-08       Impact factor: 15.828

6.  Minimalist Model Systems Reveal Similarities and Differences between Membrane Interaction Modes of MCL1 and BAK.

Authors:  Olatz Landeta; Ane Landajuela; Ana Garcia-Saez; Gorka Basañez
Journal:  J Biol Chem       Date:  2015-05-18       Impact factor: 5.157

7.  mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.

Authors:  Junghui Koo; Ping Yue; Xingming Deng; Fadlo R Khuri; Shi-Yong Sun
Journal:  Mol Cell Biol       Date:  2015-04-27       Impact factor: 4.272

8.  Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.

Authors:  Timothy G Whitsett; Ian T Mathews; Michael H Cardone; Ryan J Lena; William E Pierceall; Michael Bittner; Chao Sima; Janine LoBello; Glen J Weiss; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2014-01-27       Impact factor: 5.852

9.  Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.

Authors:  Jatin Roper; Mark J Sinnamon; Erin M Coffee; Peter Belmont; Lily Keung; Larissa Georgeon-Richard; Wei Vivian Wang; Anthony C Faber; Jihye Yun; Ömer H Yilmaz; Roderick T Bronson; Eric S Martin; Philip N Tsichlis; Kenneth E Hung
Journal:  Cancer Lett       Date:  2014-02-24       Impact factor: 8.679

10.  Mcl-1 as a potential therapeutic target for human hepatocelluar carcinoma.

Authors:  Qin Yu; Zhao-Yu Liu; Qiong Chen; Ju-Sheng Lin
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.